Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 0.79 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657691 | 1.00 | NPC1 (1.00) | NPC1RAB9ATDP1MAOBGPR84 | |
| SCHEMBL29522745 | 1.00 | NPC1 (1.00) | NPC1RAB9ATDP1MAOBGPR84 | |
| SCHEMBL8960003 | 0.85 | NPC1 (0.73) | NPC1RAB9ATDP1MAOBMAPT | |
| SCHEMBL8959997 | 0.85 | NPC1 (0.73) | NPC1RAB9ATDP1MAOBMAPT | |
| SCHEMBL27984170 | 0.84 | NPC1 (0.72) | NPC1RAB9ATDP1MAOBGPR84 | |
| SCHEMBL6495175 | 0.84 | NPC1 (0.72) | NPC1RAB9ATDP1MAOBGPR84 | |
| SCHEMBL6495182 | 0.84 | NPC1 (0.72) | NPC1RAB9ATDP1MAOBGPR84 | |
| SCHEMBL8959963 | 0.82 | NPC1 (0.68) | NPC1RAB9ATDP1MAOBGPR84 | |
| SCHEMBL8959956 | 0.82 | NPC1 (0.68) | NPC1RAB9ATDP1MAOBGPR84 | |
| SCHEMBL31745446 | 0.79 | NPC1 (0.65) | NPC1RAB9ATDP1MAOBGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349999-B1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIV SAARLAND (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8912186-B2 | Allosteric protein kinase modulators | UNIVERSITAET DES SAARLANDES (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20130116308-A1 | CD36 INHIBITION TO CONTROL OBESITY AND INSULIN SENSITIVITY | CORNELL UNIVERSITY (US) | 2013-05-09 | — | — | US | disclosed |
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2349999-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | Universität des Saarlandes (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010043711-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177510-A1 | Allosteric protein kinase modulators | Universität des Saarlandes (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-5530019-A | FOR TREATMENT OF PROSTATE GLAND DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-06-25 | — | — | US | disclosed |
| EP-0648208-A1 | INDOLE DERIVATIVES AS TESTOSTERONE 5 ALPHA-REDUCTASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-04-19 | — | — | EP | disclosed |
| WO-1994022821-A1 | INDOLE DERIVATIVES AS TESTOSTERONE 5 ALPHA-REDUCTASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | AURKC, AURKA, AURKB | NPC1 2687/4885RAB9A 2902/4885TDP1 992/4885 |
| US-20130116308-A1 | CD36 INHIBITION TO CONTROL OBESITY AND INSULIN SENSITIVITY | GPR119, IRS1, INSR | NPC1 513/4885RAB9A 1364/4885TDP1 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.